Skip to main content

Renvela FDA Approval History

FDA Approved: Yes (First approved October 19, 2007)
Brand name: Renvela
Generic name: sevelamer carbonate
Dosage form: Tablets
Company: Genzyme Corporation
Treatment for: Hyperphosphatemia of Renal Failure

Renvela (sevelamer carbonate) is a calcium-free, metal-free, non-absorbed phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

Development timeline for Renvela

Oct 22, 2007Approval FDA Approves Genzyme's Renvela for Dialysis Patients
Dec 21, 2006Genzyme Files for Approval of Sevelamer Carbonate for Patients on Dialysis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.